Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a decision expected by March 10, 2027. The company also secured a $400 million non-dilutive loan to support the potential U.S. launch of lonvo-z, underscoring confidence in its gene-editing technology and growth prospects in precision medicine.
Remittix is set to add 41 new fiat currencies to its PayFi ecosystem, enhancing crypto-to-bank and bank-to-crypto transactions globally ahead of its November 24 RTX launch. This expansion aims to support more international markets and users, includin...
First Pacific Bancorp announced solid third quarter 2026 results, with total assets reaching $532 million, up $42 million from year-end 2025. Deposits increased to $449 million, and loans grew to $362 million, reflecting steady balance sheet expansio...
ICEYE and Nokia have signed a Letter of Intent with Ukraine's Ministry of Defence to collaborate on building sovereign satellite communication capabilities. This partnership aims to enhance Ukraine's defense by providing secure, high-performance sate...
Dayton T. Brown, Inc. inaugurated its new 104,000-square-foot Test & Qualification Center in Huntsville, Alabama, enhancing its capacity to support aerospace, defense, and propulsion programs. The facility's strategic location near Huntsville's aeros...
A new study by The Grossman Group reveals that while 60% of chief communications officers (CCOs) have influence at the leadership level, their communications functions lack the necessary systems, skills, and AI capabilities to fully meet their mandat...
